Interest in peptides for weight loss beyond GLP-1 is surging as compounding rules tighten. This guide shows providers how to integrate the evidence into a compliant program.
Patients are asking about peptides for weight loss beyond GLP-1 more than ever, usually after reading about a compound they found online or heard about from a friend. The honest answer, category by category, is that nothing else comes close to the evidence base behind semaglutide and tirzepatide. That's not a marketing line — it's what happens when you actually check the trial data against what's being sold as an alternative. At the same time, the compounded-GLP-1 pathway that many practices leaned on has narrowed sharply since 2025, which means providers need a compliant answer for patients asking about weight-management peptides, not just a caveat. This guide lays out what the evidence actually supports, what changed in the compounding rules, and how to build a compliant program around it.
In this article
Clinical Evidence
GLP-1 receptor agonists work by increasing glucose-dependent insulin secretion, reducing glucagon, delaying gastric emptying, and regulating appetite centrally. Hypoglycemia is uncommon with a GLP-1 alone, though the risk rises when combined with insulin or insulin secretagogues. The clinical trial data behind this mechanism is what separates GLP-1s from nearly everything else marketed for weight loss.
In STEP 1, once-weekly semaglutide 2.4 mg produced a mean body-weight change of −14.9% versus −2.4% for placebo at 68 weeks, with 86.4% of patients achieving at least 5% weight loss, 69.1% at least 10%, and 50.5% at least 15% (versus 31.5%, 12.0%, and 4.9% for placebo). STEP 5 followed patients for two years and found the effect held: −15.2% versus −2.6% for placebo at week 104, with 77.1% of patients reaching at least 5% weight loss versus 34.4% on placebo. Gastrointestinal adverse events were more common with semaglutide (82.2% versus 53.9%), though mostly mild to moderate.
SURMOUNT-1 tested tirzepatide, a dual GIP/GLP-1 receptor agonist, at three doses: −15.0% at 5 mg, −19.5% at 10 mg, and −20.9% at 15 mg, versus −3.1% for placebo at 72 weeks. Between 85% and 91% of patients across the three doses achieved at least 5% weight loss, versus 35% on placebo. Tirzepatide's dual mechanism makes it a distinct molecule with its own dosing, contraindications, and labeled products — not simply "a stronger GLP-1," and it shouldn't be described to patients that way.
| Trial | Agent / period | Mean weight change vs placebo | ≥5% loss | ≥10% loss | ≥15% loss |
|---|---|---|---|---|---|
| STEP 1 | Semaglutide 2.4 mg / 68 weeks | −14.9% vs −2.4% | 86.4% vs 31.5% | 69.1% vs 12.0% | 50.5% vs 4.9% |
| STEP 5 | Semaglutide / 104 weeks | −15.2% vs −2.6% | 77.1% vs 34.4% | — | — |
| SURMOUNT-1 | Tirzepatide 5 mg / 72 weeks | −15.0% vs −3.1% | 85%–91% vs 35% across the three doses | — | — |
| SURMOUNT-1 | Tirzepatide 10 mg / 72 weeks | −19.5% vs −3.1% | 85%–91% vs 35% across the three doses | — | — |
| SURMOUNT-1 | Tirzepatide 15 mg / 72 weeks | −20.9% vs −3.1% | 85%–91% vs 35% across the three doses | — | — |
STEP 1 — Semaglutide 2.4 mg / 68 weeks
−14.9% vs −2.4%
≥5% loss: 86.4% vs 31.5% • ≥10%: 69.1% vs 12.0% • ≥15%: 50.5% vs 4.9%
STEP 5 — Semaglutide / 104 weeks
−15.2% vs −2.6%
≥5% loss: 77.1% vs 34.4%
SURMOUNT-1 — Tirzepatide / 72 weeks
−15.0% at 5 mg; −19.5% at 10 mg; −20.9% at 15 mg vs −3.1% placebo
≥5% loss: 85%–91% across doses vs 35% placebo
Product & Indication
The same active ingredient can carry different labels depending on the product, and that distinction has real consequences for prescribing and documentation. Zepbound (tirzepatide) is the weight-management product, also indicated for moderate-to-severe obstructive sleep apnea in patients with obesity; Mounjaro, the same molecule, is labeled for type 2 diabetes. The same split applies to semaglutide (Wegovy for weight management, Ozempic for diabetes) and liraglutide (Saxenda for weight management, Victoza for diabetes). Prescribing the diabetes-labeled product for a weight-management indication, or vice versa, is an off-label decision that should be documented as such, not treated as interchangeable branding.
Tirzepatide
Zepbound: weight management and moderate-to-severe obstructive sleep apnea in patients with obesity. Mounjaro: type 2 diabetes.
Semaglutide
Wegovy: weight management. Ozempic: diabetes.
Liraglutide
Saxenda: weight management. Victoza: diabetes.
Reading GLP-1 trial data and translating it accurately for a patient is exactly the skill the IAPAM peptide therapy course is built to develop, particularly as more agents and indications enter this category.
Compounding & Alternatives
The compounding pathway that many practices used for GLP-1s has narrowed considerably. FDA determined the tirzepatide injection shortage was resolved on December 19, 2024, and the semaglutide shortage followed on February 21, 2025 — both dates that closed the shortage-based legal basis for routine compounding. FDA has since proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list entirely. That exclusion is proposed, not finalized, and providers should verify current FDA guidance before assuming a given compounding pathway is still open.
Where compounded GLP-1s are still in the picture, the risk profile is real and specific. FDA has documented dosing errors tied to concentration and "units" confusion, use of salt forms like semaglutide sodium or semaglutide acetate that are not the same active ingredient as the approved drug, cold-chain failures during shipping, and fraudulent labels claiming pharmacy compounding that never happened. A Stanford Medicine review of 2024 adverse-event data reported that 95% of adverse events associated with GLP-1s that year were tied to how the product was dosed or administered rather than to the drug itself — consistent with what happens when patients are left to measure their own doses from multidose vials instead of using a pre-filled, FDA-approved pen. Any provider still working with a compounded GLP-1 supplier should be verifying the pharmacy and the specific prescription directly, not assuming a label is accurate.
The "beyond GLP-1" search interest usually leads to AOD-9604, a modified human growth hormone fragment marketed online for fat loss. It is not FDA-approved and is not a legitimate US compounded preparation. A 536-participant obesity study testing AOD-9604 failed its primary endpoint, and FDA's own review found insufficient evidence of effectiveness alongside safety-data gaps; development was discontinued. When a patient asks what else is out there, this is the honest answer: the peptide most associated with "beyond GLP-1" weight loss is the one that failed its own clinical trial.
| Risk | What can go wrong | Verification step |
|---|---|---|
| Dosing / concentration errors | Errors tied to concentration and "units" confusion | Verify the pharmacy and the specific prescription directly. |
| Salt-form substitution | Semaglutide sodium or semaglutide acetate are not the same active ingredient as the approved drug | Verify the pharmacy and the specific prescription directly. |
| Cold-chain failure | Cold-chain failures during shipping | Verify the pharmacy and the specific prescription directly. |
| Fraudulent labeling | Labels claiming pharmacy compounding that never happened | Verify the pharmacy and the specific prescription directly. |
Dosing / concentration errors
Concentration and "units" confusion
Verify the pharmacy and the specific prescription directly.
Salt-form substitution
Semaglutide sodium or semaglutide acetate are not the same active ingredient as the approved drug
Verify the pharmacy and the specific prescription directly.
Cold-chain failure
Cold-chain failures during shipping
Verify the pharmacy and the specific prescription directly.
Fraudulent labeling
Labels claiming pharmacy compounding that never happened
Verify the pharmacy and the specific prescription directly.
Program Design
GLP-1s also carry a drug-interaction consideration worth building into any weight-management workup: because they slow gastric emptying, they can affect the absorption of narrow-therapeutic-index oral medications, including oral contraceptives, levothyroxine, and warfarin. Counsel patients on timing and monitor accordingly rather than treating this as a footnote.
Obesity is a chronic, relapsing disease, and medication addresses one part of it. GLP-1 therapy reduces the biologic drivers of hunger, but it does not replace nutrition support, activity, sleep, and behavioral care — and program goals should be framed around health and function, not the scale alone. That framing matters clinically, and it also happens to be what separates a compliant, durable weight-management offering from a compounding workaround dressed up as one.
Building that kind of program — approved products, documented off-label decisions where relevant, drug-interaction screening, and support structured around the whole patient — is precisely what IAPAM's Certified Medical Weight Management Provider™ program is built to teach. If compounded GLP-1s were part of how your practice served weight-management patients, this is the compliant next step, not a smaller version of the same workaround.
Key Takeaways
GLP-1 efficacy is real and substantial: semaglutide produced −14.9% to −15.2% weight change versus placebo across STEP 1 and STEP 5, and tirzepatide produced up to −20.9% in SURMOUNT-1.
Zepbound, Mounjaro, Wegovy, Ozempic, Saxenda, and Victoza carry different FDA-labeled indications despite sharing active ingredients — prescribing across labels is an off-label decision that needs documentation.
The compounded-GLP-1 pathway has narrowed sharply since the 2024–2025 shortage resolutions, and FDA has proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list — verify current status before relying on it.
"Beyond GLP-1" weight-loss peptides don't have the evidence GLP-1s do — AOD-9604, the most searched-for example, failed its primary endpoint in a 536-participant trial and was discontinued.
A compliant weight-management program is built on approved products, documentation, and whole-patient support, not a compounding workaround. The Certified Medical Weight Management Providerâ„¢ program is built for that transition.
For the broader peptide landscape this fits into, see our peptide therapy for providers hub. Providers weighing body-composition peptides alongside GLP-1 therapy may also find our growth hormone peptide comparison useful for that adjacent conversation.
Frequently asked questions
None have evidence approaching what supports semaglutide and tirzepatide. Tirzepatide itself is a dual GIP/GLP-1 agonist, not a separate category. AOD-9604, the most commonly searched "beyond GLP-1" option, failed its primary endpoint in a 536-participant trial and was never approved.
In STEP 1, semaglutide 2.4 mg produced −14.9% mean weight change versus −2.4% for placebo at 68 weeks. In SURMOUNT-1, tirzepatide 15 mg produced −20.9% versus −3.1% for placebo at 72 weeks. STEP 5 confirmed semaglutide's effect held at two years.
Same active ingredient, different labels. Zepbound is FDA-approved for weight management and moderate-to-severe obstructive sleep apnea in patients with obesity; Mounjaro is approved for type 2 diabetes. Prescribing one for the other's indication is off-label and should be documented.
The legal basis has narrowed. Both the tirzepatide and semaglutide shortages were declared resolved in late 2024 and early 2025, and FDA has proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. That exclusion is proposed, not final — verify current FDA guidance before relying on a specific compounding pathway.
No adequate evidence supports it. A 536-participant obesity trial testing AOD-9604 failed its primary endpoint, FDA's review found insufficient evidence of effectiveness and safety-data gaps, and development was discontinued. It is not FDA-approved and not a legitimate compounded product in the US.
No. Obesity is a chronic, relapsing disease, and medication addresses the biologic drivers of hunger without replacing nutrition, activity, sleep, and behavioral support. Program goals should include health and function, not weight alone.
Next Step
Medical Weight Management Training
View Training →Peptide Therapy Hub
Back to Hub →Growth Hormone Peptide Comparison
Read the Comparison →Terms and conditions apply. Offer expires September 30.